IL12B Antibodies

Interleukin-12 subunit beta (IL12B)

Cytokine that can act as a growth factor for activated T and NK cells, enhance the lytic activity of NK/lymphokine- activated killer cells, and stimulate the production of IFN-gamma by resting PBMC. .

Gene Information

Human
Gene Name:	IL12B
Uniprot:	P29460
Entrez:	3593

Family

Belongs to:
IL-12B family

Alternative Names

CLMF p40; CLMF; CLMF2; Cytotoxic lymphocyte maturation factor 40 kDa subunit; IL12 p40; IL-12 p40; IL-12 subunit p40; IL12B; IL-12B; IL-12BNK cell stimulatory factor chain 2; interleukin 12, p40; interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocytematuration factor 2, p40); interleukin-12 beta chain; interleukin-12 subunit beta; natural killer cell stimulatory factor, 40 kD subunit; NKSF; NKSF2; NKSF2IL12, subunit p40

Molecular Weight

Mass (kDA):
37.169 kDA

Genomic Context

Human
Location:	5q33.3
Sequence:	5; NC_000005.10 (159314780..159330487, complement)

Subcellular Localizations

Secreted.

Diseases

• Psoriasis
• Crohn Disease
• Autoimmune Reaction
• Inflammation
• Autoimmune Diseases
• Diabetes Mellitus
• Diabetes Mellitus, Insulin-dependent
• Tuberculosis
• Infective Disorder
• Inflammatory Bowel Diseases
• Arthritis
• Mycobacterium Infections
• Colitis

• Cholangiocarcinoma
• Ulcer
• Dysequilibrium Syndrome
• Intestinal Diseases
• Malaria
• Arthritis, Psoriatic
• Ulcerative Colitis

Interacting Proteins

• IL12A
• IL23A
• Il23a

Pathways

• Pathogenesis
• Immune Response
• Secretion
• Cytokine Production
• Autophagy
• Localization
• Macrophage Activation
• Inflammatory Response
• Innate Immune Response
• Cell Differentiation
• Cell Activation
• Complement Activation
• Adaptive Immune Response

• Virulence
• Cellular Response To Dsrna
• T Cell Activation
• Interferon-gamma Production
• Proteolysis
• Hypersensitivity
• Tropism

PTMs

• Phosphorylation
• Cleavage
• Acetylation
• Glycosylation

• Deacetylation
• Methylation
• Acylation
• Ubiquitination

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/IL12B

Boster Bio: The Best Uses Of The IL12B Marker

The Ill12B marker is a subunit of Interleukin 12. Its use in cancer immunotherapy and vaccines can expand the range of solid tumor targets. We will review the main advantages of IL12B as well as how they can contribute to your research. Boster's research and development efforts are backed by its product credits, which are awarded to the first reviewers and scientists across the world.

IL12b p40 is a subunit in Interleukin 12

The IL12B subunit is a part of the cytokine Interleukin 12. Interleukin 12 stimulates the activity of natural killer cells and T cells. This disulfide-linked heterodimer consists of two subunits: A 40-kDa cytokine receptor subunit and a 35-kDa subunit for cytokine receptors. Macrophages that are activated produce IL12B, which is a key mediator in TH2 cell development and maintenance as well as protection against intracellular pathogens.

The gene IL-12 encodes a 328-amino acids polypeptide. It is located on chromosome 531 and includes four N-glycosylation-related potential sites as well as four intramolecular diulfide bonds. There is no transmembrane-specific domain in IL-12B which is an essential characteristic of the cytokine. It is not known which subunits of IL-12b in humans are present.

In a study of a Pakistani girl who had a genetic mutation in IL12b the p40 gene, a variant in the IL12b p40 gene has been linked to an increase in IL-12 p70 synthesis. Interestingly, the p40 polymorphism is not associated with susceptibility to CD. It could, however, affect the progression of the disease in certain subsets.

There is a lack consensus regarding the role played by IL-12b p-40 in the inflammatory process of GCA. However, it is not clear if IL-23p40 plays a role in regulating the activity of IL-23 in inflammatory diseases, which has a potential to worsen the condition. In addition, a p40/IL-12b subunit neutralization of IL-23p40 reduces the activity of TH27 inducers.

The IL12B p40 protein is an interleukin subunit found in several different kinds of cells. It is not a component of IL-12 or IL-23, but has no biological activity. Its polymorphism has been associated with multiple sclerosis , and is thought to play a role in asthma in children. If you have any questions regarding IL12b 40, please get in touch with us.

Researchers have discovered that coffee arabinogalactan may stimulate the production of IL-12 in splenocytes in mice. The immune response to malaria was not hindered by coffee's effects. Additionally applying coffee directly to mice suppressed the secretion of IL-12p40 from CD11c+ dendritic cells.

It may increase the effectiveness of cancer vaccines.

Cancer vaccines target tumor cells and are different from conventional vaccines. Conventional vaccines cause humoral immune response. The cancer vaccines however, are designed to generate an effective immune response against tumor reactive antigens. Tumors utilize several strategies to evade antitumor T cells. These strategies include checkpoint receptor signals, accumulation of regulatory immune cell cells and changes in the level of oxygenation of the tissues.

To improve the efficacy of whole tumor cell vaccines, tumor cells are genetically modified in order to include various immune response-related molecules including IL-21 and IL-7. This method effectively slowed down the development of mouse breast tumors. The vaccines should be examined further, since they possess a significant potential to boost the effectiveness of cancer vaccines. Further research is required to determine the best cancer vaccine.

Combination therapy has revolutionized cancer treatment. It is often used in conjunction with chemotherapy to provide longer-lasting results. This approach could boost the effectiveness of cancer vaccines. This is a promising approach for clinical trials. While some patients may benefit from checkpoint blockade therapies however, many patients may not. In the end, a variety of strategies are being created to overcome the resistance of tumors such as radiotherapy and cancer vaccines.

Peptide-based vaccines against cancer require the identification and analysis of epitopes within T cells that are CD8+. This is necessary to activate CTL tumor immunity. However, a fusion vaccine that includes the antigen MAGE-1Hsp70 is more effective than a combination HP70 and MAGE-1 in producing greater antibody titers. The combination of these antigens can also boost the activity of cancer vaccines.

DNA vaccines can boost the immune response of patients, but their immunogenicity is limited. DNA vaccines are not very immunegenic, despite their high safety and efficacy. However, DNA vaccines that include human chimeric antigens have been tested clinically and have shown efficacy against tumors in animals. For human use the chimeric DNA cancer vaccines are a better option over DNA cancer vaccines.

Current research shows that tumor-specific antigens are key to the effectiveness of cancer vaccines. Contrarily, non-targeted vaccines are based on tumor lysates and generate T cells that respond to common tumor antigens. Antigens are expressed in malignant as well as healthy tissues. They are often overexpressed in malignant cells, but expressed at low levels within healthy tissues in the majority of cases. These include melanoma differentiation antigens and antigens associated with testes.

While personalized cancer vaccines based on Neoantigens have demonstrated promising results, their use is limited by the high number of mutated antibodies, that limit their ability to be applied to all types of cancers. For this reason, finding high-quality, high-quality neoantigens will be crucial for the creation of cancer vaccines. The goal is to increase the amount of T cells that are tumor-specific and have a good anti-tumor response.